RE
VRNA

RBC Europe’s Verona Pharma VRNA Stock Holding History

RBC Europe’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$3K Hold
726
– – ﹤0.01% 575
2022
Q1 		$4K Hold
726
– – ﹤0.01% 580
2021
Q4 		$5K Sell
726
-3,689
-84% -$18.8K ﹤0.01% 574
2021
Q3 		$24.2K Hold
4,415
– – ﹤0.01% 734
2021
Q2 		$28.9K Hold
4,415
– – ﹤0.01% 723
2021
Q1 		$36.9K Hold
4,415
– – ﹤0.01% 624
2020
Q4 		$30.9K Buy
+4,415
New +$29.8K ﹤0.01% 620

Other funds holding VRNA

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RBC Europe's VRNA Position: Q2 2022 in Review

RBC Europe held its Verona Pharma (VRNA) position steady in Q2 2022 at 726 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

RBC Europe first reported a position in VRNA in Q4 2020 and has held it in 7 quarters since. The position peaked at $36.9K in Q1 2021. 40 funds tracked by Wall St. Rank hold VRNA as of Q2 2022.

  • RBC Europe held 726 shares of Verona Pharma worth $3K as of Q2 2022.
  • RBC Europe left its Verona Pharma share count unchanged in Q2 2022.
  • Verona Pharma made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #575 holding.
  • RBC Europe first reported a position in Verona Pharma in Q4 2020 and has held it in 7 quarters since.
  • RBC Europe's Verona Pharma position peaked at $36.9K in Q1 2021.
  • 40 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.